Article Type
Changed
Thu, 12/15/2022 - 15:07
Display Headline
Improving Treatment Options for Chronic Myelogenous Leukemia
Dr. Benjamin Powers and Dr. Suman Kambhampati discuss the improvements they have seen in the survival of patients with CML and how genetics and other factors play a role in treating the disease.

Recently, Federal Practitioner talked with Benjamin Powers, MD, and Suman Kambhampati, MD, about factors that come into play when treating patients with chronic myelogenous leukemia (CML) and the dramatic improvements in treatment that have been made. To find out more about these factors and improvements, read Blast Phase Chronic Myelogenous Leukemia from the August 2014 issue.

Dr. Powers is a fellow and Dr. Kambhampati is an associate professor of medicine, both in the Department of Internal Medicine, Division of Hematology/Oncology, at the University of Kansas Medical Center in Kansas City, Kansas. Dr. Kambhampati is also a staff physician in the Hematology/Oncology Division at the Kansas City VAMC in Kansas City, Missouri.

Publications
Topics
Legacy Keywords
Leukemia, Chronic Myelogenous leukemia, cancer, oncology, hematology, veterans affairs, blast phase, CML
Sections
Related Articles
Dr. Benjamin Powers and Dr. Suman Kambhampati discuss the improvements they have seen in the survival of patients with CML and how genetics and other factors play a role in treating the disease.
Dr. Benjamin Powers and Dr. Suman Kambhampati discuss the improvements they have seen in the survival of patients with CML and how genetics and other factors play a role in treating the disease.

Recently, Federal Practitioner talked with Benjamin Powers, MD, and Suman Kambhampati, MD, about factors that come into play when treating patients with chronic myelogenous leukemia (CML) and the dramatic improvements in treatment that have been made. To find out more about these factors and improvements, read Blast Phase Chronic Myelogenous Leukemia from the August 2014 issue.

Dr. Powers is a fellow and Dr. Kambhampati is an associate professor of medicine, both in the Department of Internal Medicine, Division of Hematology/Oncology, at the University of Kansas Medical Center in Kansas City, Kansas. Dr. Kambhampati is also a staff physician in the Hematology/Oncology Division at the Kansas City VAMC in Kansas City, Missouri.

Recently, Federal Practitioner talked with Benjamin Powers, MD, and Suman Kambhampati, MD, about factors that come into play when treating patients with chronic myelogenous leukemia (CML) and the dramatic improvements in treatment that have been made. To find out more about these factors and improvements, read Blast Phase Chronic Myelogenous Leukemia from the August 2014 issue.

Dr. Powers is a fellow and Dr. Kambhampati is an associate professor of medicine, both in the Department of Internal Medicine, Division of Hematology/Oncology, at the University of Kansas Medical Center in Kansas City, Kansas. Dr. Kambhampati is also a staff physician in the Hematology/Oncology Division at the Kansas City VAMC in Kansas City, Missouri.

Publications
Publications
Topics
Article Type
Display Headline
Improving Treatment Options for Chronic Myelogenous Leukemia
Display Headline
Improving Treatment Options for Chronic Myelogenous Leukemia
Legacy Keywords
Leukemia, Chronic Myelogenous leukemia, cancer, oncology, hematology, veterans affairs, blast phase, CML
Legacy Keywords
Leukemia, Chronic Myelogenous leukemia, cancer, oncology, hematology, veterans affairs, blast phase, CML
Sections
Disallow All Ads